Patents Assigned to AMO Pharma Ltd.
  • Methods of synthesizing farnesyl dibenzodiazepinones
    Patent number: 12600703
    Abstract: The present invention is directed to synthetic means for producing farnesyl dibenzodiazepinone compounds, including AMO-01.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: April 14, 2026
    Assignee: AMO PHARMA LTD.
    Inventors: Bernard Matthew Kiernan, Thomas R. Bailey, Binfeng Li
  • METHODS OF TREATING PHELAN MCDERMID SYNDROME USING FARNESYL DIBENZODIAZEPINONES
    Publication number: 20230270752
    Abstract: Methods for treating Phelan McDermid Syndrome (PMS) in subjects having the disorder or in subjects predisposed to develop the disorder via administration of farnesyl dibenzodiazepinone compounds are provided. The use of farnesyl dibenzodiazepinone compounds in the manufacture of a medicament for treating a subject having PMS is provided as well.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 31, 2023
    Applicant: AMO Pharma Ltd.
    Inventors: Michael Snape, Patricia Cogram, Robert Deacon
  • METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND
    Publication number: 20230241038
    Abstract: The use of 2,4-disubstituted thiadiazolidinone (TDZD) compounds, such as Tideglusib (4-Benzyl-2-naphthalen-1-yl-[1,2,4]thiadiazolidine-3,5-dione), in methods of inhibiting RNA molecules comprising abnormal trinucleotide repeats (such as CUG) in their sequences is provided. Such methods include methods of inhibiting RNA molecules having abnormal repeat sequences, as well as methods of treating and/or preventing diseases associated with the presence of RNA molecules having abnormal repeat sequences, such as myotonic dystrophy type 1 (DM1).
    Type: Application
    Filed: February 10, 2023
    Publication date: August 3, 2023
    Applicant: AMO Pharma Ltd.
    Inventor: Michael SNAPE
  • METHODS OF SYNTHESIZING FARNESYL DIBENZODIAZEPINONES
    Publication number: 20230192629
    Abstract: The present invention is directed to synthetic means for producing farnesyl dibenzodiazepinone compounds, including AMO-01.
    Type: Application
    Filed: May 28, 2021
    Publication date: June 22, 2023
    Applicant: AMO Pharma Ltd.
    Inventors: Bernard Matthew Kiernan, Thomas R. Bailey, Binfeng LI
  • METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND
    Publication number: 20220387399
    Abstract: The use of 2,4-disubstituted thiadiazolidinone (TDZD) compounds, such as Tideglusib (4-Benzyl-2-naphthalen-1-yl-[1,2,4]thiadiazolidine-3,5-dione), in methods of inhibiting RNA molecules comprising abnormal trinucleotide repeats (such as CUG) in their sequences is provided. Such methods include methods of inhibiting RNA molecules having abnormal repeat sequences, as well as methods of treating and/or preventing diseases associated with the presence of RNA molecules having abnormal repeat sequences, such as myotonic dystrophy type 1 (DM1).
    Type: Application
    Filed: May 20, 2022
    Publication date: December 8, 2022
    Applicant: AMO Pharma Ltd.
    Inventor: Michael SNAPE
  • METHODS OF TREATING PHELAN MCDERMID SYNDROME USING FARNESYL DIBENZODIAZEPINONES
    Publication number: 20200330478
    Abstract: Methods for treating Phelan McDermid Syndrome (PMS) in subjects having the disorder or in subjects predisposed to develop the disorder via administration of farnesyl dibenzodiazepinone compounds are provided. The use of farnesyl dibenzodiazepinone compounds in the manufacture of a medicament for treating a subject having PMS is provided as well.
    Type: Application
    Filed: October 25, 2018
    Publication date: October 22, 2020
    Applicant: AMO Pharma Ltd.
    Inventors: Michael Snape, Patricia Cogram, Robert Deacon